KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to $60.7 million.

  • Jazz Pharmaceuticals' Shares Outstanding (Weighted Average) fell 1.77% to $60.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.7 million, marking a year-over-year decrease of 1.77%. This contributed to the annual value of $60.5 million for FY2024, which is 3.97% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Shares Outstanding (Weighted Average) of $60.7 million as of Q3 2025, which was down 1.58% from $61.6 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $64.0 million during Q2 2023, and its lowest value of $56.3 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $62.2 million, with a median of $62.3 million in 2024.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Shares Outstanding (Weighted Average) climbed by 10.33% in 2021 and then decreased by 3.97% in 2024.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $61.5 million in 2021, then grew by 2.43% to $63.0 million in 2022, then decreased by 0.01% to $63.0 million in 2023, then declined by 3.97% to $60.5 million in 2024, then dropped by 1.77% to $60.7 million in 2025.
  • Its last three reported values are $60.7 million in Q3 2025, $61.6 million for Q2 2025, and $60.7 million during Q1 2025.